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Management and Outcomes of
Cardiogenic Shock in Cardiac ICUs With
Versus Without Shock Teams
Alexander I. Papolos, MD,a Benjamin B. Kenigsberg, MD,a David D. Berg, MD,b Carlos L. Alviar, MD,c
Erin Bohula, MD, PHD,b James A. Burke, MD, PHD,d Anthony P. Carnicelli, MD,e Sunit-Preet Chaudhry, MD,f
Stavros Drakos, MD, PHD,g Daniel A. Gerber, MD,h Jianping Guo, MAS,b James M. Horowitz, MD,c Jason N. Katz, MD,e
Ellen C. Keeley, MD,i Thomas S. Metkus, MD,j Jose Nativi-Nicolau, MD,g Jeffrey R. Snell, MD,k
Shashank S. Sinha, MD,l Wayne J. Tymchak, MD,m Sean Van Diepen, MD,m David A. Morrow, MD,b,*
Christopher F. Barnett, MD,a,* on behalf of the Critical Care Cardiology Trials Network Investigators

ABSTRACT
BACKGROUND Single-center studies suggest that implementation of multidisciplinary cardiogenic shock (CS) teams is
associated with improved CS survival.
OBJECTIVES The aim was to characterize practice patterns and outcomes in the management of CS across multiple
centers with versus without shock teams.
METHODS The Critical Care Cardiology Trials Network is a multicenter network of cardiac intensive care units (CICUs) in
North America. All consecutive medical admissions to each CICU (n ¼ 24) were captured during annual 2-month
collection periods (2017-2019; n ¼ 6,872). Shock management and CICU mortality among centers with versus without
shock teams were compared using inverse probability weighting.
RESULTS Ten of the 24 centers had shock teams. Among 1,242 CS admissions, 44% were at shock team centers. The
groups were well-balanced with respect to demographics, shock etiology, Sequential Organ Failure Assessment score,
biochemical markers of end organ dysfunction, and invasive hemodynamics. Centers with shock teams used more pulmonary artery catheters (60% vs 49%; adjusted odds ratio [OR]: 1.86; 95% CI: 1.47-2.35; P < 0.001), less overall
mechanical circulatory support (MCS) (35% vs 43%; adjusted OR: 0.74; 95% CI: 0.59-0.95; P ¼ 0.016), and more
advanced types of MCS (53% vs 43% of all MCS; adjusted OR: 1.73; 95% CI: 1.19-2.51; P ¼ 0.005) rather than intra-aortic
balloon pumps. The presence of a shock team was independently associated with lower CICU mortality (23% vs 29%;
adjusted OR: 0.72; 95% CI: 0.55-0.94; P ¼ 0.016).
CONCLUSIONS In this multicenter observational study, centers with shock teams were more likely to obtain invasive
hemodynamics, use advanced types of MCS, and have lower risk-adjusted mortality. A standardized multidisciplinary
shock team approach may improve outcomes in CS. (J Am Coll Cardiol 2021;78:1309–1317) © 2021 by the American
College of Cardiology Foundation.
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C

ABBREVIATIONS
AND ACRONYMS
AMI-CS = acute myocardial

ardiogenic shock (CS) is a highly

treatment of CS among advanced cardiac intensive

morbid clinical syndrome of low

care units (CICUs) with versus without shock teams in

cardiac output and consequent end

a well-characterized cohort from a large multicenter

organ hypoperfusion (1). Despite therapeutic

infarction–related cardiogenic
shock

advancements, mortality from CS remains

CCCTN = Critical Care

high

Cardiology Trials Network

sensitive nature of the complex medical,

CICU = cardiac intensive care

catheter-based,

unit

used in caring for patients with CS, some cen-

CS = cardiogenic shock

ters have developed and implemented multi-

ECMO = extracorporeal

disciplinary

membrane oxygenation

(30%-50%)

(1-4).
and

“shock

Given

the

surgical

teams”

include

representation from critical care cardiology,

ICU = intensive care unit

advanced heart failure and transplant cardi-

IPW = inverse probability

ology, interventional cardiology, extracorpo-

weighted

real membrane oxygenation (ECMO), and

MCS = mechanical circulatory

cardiac surgery specialties. The purpose of

support

such a shock team is to facilitate early shock

OR = odds ratio

recognition and expedite multidisciplinary

PAC = pulmonary artery

discussions regarding evaluation and man-

catheter

agement, including the need for timely me-

SCAI = Society for
Cardiovascular Angiography &

chanical

Interventions

appropriate device selection when indicated.

SOFA = Sequential Organ

Single-center observational studies have sug-

Failure Assessment

gested that the implementation of multidis-

VA-ECMO = venoarterial

circulatory

support

(MCS)

and

ciplinary shock teams may be associated

extracorporeal membrane

with improved CS outcomes; however, these

oxygenation

SEE PAGE 1318

time-

treatments

that

North American registry.

reports are limited in size, and multiinstitutional data exploring the association with
treatment practices, critical care resource use, and
outcomes are lacking (5-8).
The objective of this analysis was to evaluate
contemporary practice patterns and outcomes in the

METHODS
STUDY POPULATION. The Critical Care Cardiology

Trials Network (CCCTN) is an investigator-initiated
collaborative research network of American Heart
Association level 1 CICUs located in the United States
and Canada. The methods of recruitment and data
acquisition have been previously described in detail
(9). Scientiﬁc oversight of the CCCTN is conducted by
its academic executive and steering committees, and
the data are submitted to a central data coordinating
center (TIMI [Thrombolysis In Myocardial Infarction]
Study Group, Boston, Massachusetts). For this analysis, each participating center (n ¼ 24) contributed
annual 2-month “snapshots” of all consecutive medical admissions to the CICU from 2017 to 2019.
Cardiogenic shock was deﬁned as sustained hemodynamic impairment (ie, systolic blood pressure
of <90 mm Hg or the need for inotropic or vasopressor support) with evidence of end organ hypoperfusion determined to be due to a primary cardiac
etiology by the site investigator (1). Similarly, a
determination of the predominantly failing ventricle
(left, right, or both) was made by each site investigator. Each center also provided center-level information regarding hospital characteristics during the
study period (eg, size, academic afﬁliation). Centers
that self-identiﬁed as having established shock teams

T A B L E 1 Center and Overall Patient Characteristics

completed questionnaires describing shock team
Shock
Team

No Shock
Team

10

14

#500

0 (0)

5 (36)

>500-#1,000

8 (80)

6 (43)

Number of centers

membership, structure, and operations.
P Value

Hospital size, number of beds

>1,000

0.084

3 (21)

10 (100)

11 (79)

0.12

Urban

10 (100)

9 (64)

0.053

2,898

3,974

290

284

Average number of CICU admissions per center
Patients admitted with cardiogenic shock
Duration of CICU stay, days
SOFA score
Overall CICU mortality

Review Board at Brigham and Women’s Hospital
(Data Coordinating Center), MedStar Washington
Hospital Center, and each of the participating centers.

2 (20)

Academic
CCCTN population during study period
(not restricted to cardiogenic shock)

The CCCTN Registry protocol and waiver of
informed consent were approved by the Institutional

No

personal

identifying

health

information

is

collected in the Registry database.
CLASSIFICATION

OF

MCS. Advanced

MCS

was

deﬁned as Impella (2.5, CP, 5.0, 5.5 or RP; Abiomed),

546 (19)

696 (18)

0.16

TandemHeart (LivaNova), venoarterial ECMO (VA-

2.2 (1.1-4.8)

2.3 (1.2-4.9)

0.026

ECMO), or temporary or durable surgical ventricular

4 (2-7)

3 (1-6)

<0.0001

283 (9.8)

348 (8.8)

0.15

Values are n, n (%), or median (interquartile range). The Wilcoxon rank sum test was used for continuous
variables, and the chi-square test or Fisher exact test was used for categorical variables.
CCCTN ¼ Cardiac Critical Care Trials Network; CICU ¼ cardiac intensive care unit; SOFA ¼ Sequential Organ
Failure Assessment.

assist devices implanted for the management of
CS (10).
The initial MCS device used as well as the total
number and types of MCS devices used during CS
admissions were identiﬁed. In cases where the temporary MCS strategy involved multiple concurrent
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devices (eg, VA-ECMO with Impella as a left ventricular venting mechanism), a hierarchical classiﬁcation

T A B L E 2 Characteristics of Patients With Cardiogenic Shock

Shock Team
(n ¼ 546)

No Shock Team
(n ¼ 696)

P Value

Age, y

65 (54-75)

63 (54-72)

0.007

Female

195 (35.7)

219 (31.5)

0.12
0.001

scheme was used to identify the device providing the
highest level of hemodynamic support (temporary
surgical ventricular assist device > VA-ECMO > TandemHeart > Impella > intra-aortic balloon pump). In

Race

cases of outside hospital transfer patients who un-

White

353 (64.7)

390 (56.0)

derwent escalation to a device with a higher level of

African American

120 (22.0)

162 (23.3)

hemodynamic support at the CCCTN center, the de-

Other

73 (13.4)

144 (20.7)

250 (45.8)

338 (48.6)

0.080
0.96

vice selected following transfer to the CCCTN center

Transfers from outside hospitals

was deﬁned as the initial MCS device. In cases where

Out-of-hospital cardiac arrest

61 (12.0)

77 (11.8)

In-hospital cardiac arrest

67 (13.1)

83 (12.7)

288 (52.8)

401 (57.6)

0.087

7 (5-11)

8 (5-11)

0.82
<0.001

patients were transferred on a speciﬁc MCS device
and there was no escalation at the CCCTN center, the
device placed at the referring center was deﬁned as

Prior history of heart failure
SOFA score
LVEF during shock presentation, %

the initial device.

$50

87 (17.09)

88 (13.79)

STATISTICAL ANALYSIS. Continuous variables were

20-<50

267 (52.46)

255 (39.97)

<20

155 (30.45)

295 (46.24)

compared with the Wilcoxon rank sum test, and categorical variables were compared using the chisquare or Fisher exact tests, where appropriate.
Inverse probability weighted (IPW) modeling was

Cardiogenic shock etiology
AMI-CS

147 (26.9)

193 (27.7)

Non–AMI-CS

399 (73.1)

503 (72.3)

Cardiogenic shock phenotype

used to compare key elements of shock management,

LV failure

261 (47.9)

288 (41.4)

such as the use of pulmonary artery catheters (PACs)

RV failure

46 (8.4)

51 (7.3)

and MCS, and the primary outcome of CICU mortality

Biventricular failure

140 (25.7)

240 (34.5)

between centers with versus without shock teams.

Other (arrhythmia, valvular,
tamponade, and so on)

98 (18.0)

116 (16.7)

The IPW model was based on a priori variables of

0.75

0.0096

SCAI stage of CS

clinical relevance and included covariates for age,

C

124 (29.5)

142 (25.04)

sex, Sequential Organ Failure Assessment (SOFA)

D

144 (34.29)

228 (40.21)

E

152 (36.19)

197 (34.74)

Admission lactate, mmol/L

2.3 (1.4-4.6)

2.3 (1.4-4.4)

0.92

Admission creatinine, mg/dL

1.5 (1.1-2.3)

1.6 (1.1-2.3)

0.98

score, in-hospital and out-of-hospital cardiac arrest
preceding shock presentation, hospital size (dichotomized at 750 beds), CS phenotype (left ventricular
predominant, right ventricular predominant, biven-

0.1232

End organ injury

Peak lactate, mmol/L

3.0 (1.8-6.3)

3.2 (1.8-6.4)

0.73

tricular failure, or other) and Society for Cardiovas-

Peak creatinine, mg/dL

1.8 (1.3-3.1)

2.1 (1.4-3.3)

0.060

cular Angiography and Interventions (SCAI) stage of

Peak AST, mmol/L

94 (36-403)

126 (47-457)

0.007

CS (4). Standardized differences before and after

Peak ALT, mg/dL

62 (29-256)

73 (32-316)

0.067

IPW

Lowest pH, arterial blood gas

7.33 (7.22-7.41)

7.32 (7.21-7.40)

0.41

adjustment

were

examined

graphically

(Supplemental Figure 1). A standardized difference
of <10% was considered an acceptable balance of
measured baseline variables between centers with
and without shock teams.
All tests were 2-sided, and a P value of <0.05 was
considered statistically signiﬁcant. Analyses were

Values are median (interquartile range) or n (%). The Wilcoxon rank sum test used for continuous variables, and
the chi-square test or Fisher exact test was used for categorical variables. Determination of cardiogenic shock
phenotype was missing in one patient from each group. Proportions of LVEF tertile and SCAI stage are reported
as percent of available data.
ALT ¼ alanine aminotransferase; AM-ICS ¼ acute myocardial infarction–related cardiogenic shock;
AST ¼ aspartate aminotransferase; CS ¼ cardiogenic shock; LV ¼ left ventricle; LVEF ¼ left ventricular ejection
fraction; non–AMI-CS ¼ nonacute myocardial infarction–related cardiogenic shock; RV ¼ right ventricle;
SCAI ¼ Society for Cardiovascular Angiography & Interventions; SOFA ¼ Sequential Organ Failure Assessment.

performed with SAS, version 9.4 (SAS Institute Inc),
and R, version Q10 3.4.3 (R Core Team).

RESULTS

were 2,898 admissions to shock team centers and

CENTER AND SHOCK TEAM CHARACTERISTICS. Ten

of 24 centers (42%) reported having a shock team.
Characteristics of the centers are reported in Table 1.
Shock teams were present only in medium and large
(>500 beds), urban, academic medical centers. Centers with shock teams had higher-acuity patients

3,974 admissions to centers without a shock team, of
which 19% and 18% were for CS, respectively. Survey
data provided by the 10 centers with shock teams
showed that the service-line representation, structure, and operations of the teams were similar across
centers (Supplemental Table 1).

overall (ie, not restricted to CS, median SOFA score 4

PATIENT CHARACTERISTICS. The sample included

versus 3; P < 0.001). During the study period, there

1,242 patients admitted with CS, 546 (44%) of whom
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shorter median CICU length of stay (4.0 vs 5.1 days;

T A B L E 3 Hemodynamics of Patients With Cardiogenic Shock

Shock Team
(n ¼ 546)

P < 0.001) (Table 4) and were less frequently treated

No Shock Team
(n ¼ 696)

P Value

with mechanical ventilation (41% vs 52%; P < 0.001)
or new renal replacement therapy (11% vs 19%;

Pulmonary artery catheter use

330 (60.4)

341 (49.0)

<0.001

Heart rate, beats/min

88 (76-105)

93 (80-110)

0.022

MAP, mm Hg

74 (66-86)

73 (65-83)

0.18

Right atrial pressure, mm Hg

15 (10-20)

13 (9-18)

0.019

admissions for CS; n ¼ 6,872), there was no signiﬁcant

P < 0.001).
Among all CICU admissions (ie, not restricted to

1.58 (1.00-2.45)

1.78 (1.13-2.58)

0.23

difference in CICU mortality between those admitted

PCWP, mm Hg

25 (19.0-30.0)

22 (17.5-28.0)

0.060

to CICUs at centers with versus without a shock team

Cardiac index, L/min/m2

1.89 (1.55-2.28)

2.01 (1.60-2.50)

0.069

(9.8% vs 8.8%; P ¼ 0.15). However, among admissions

Cardiac power output, W

0.62 (0.49-0.84)

0.64 (0.47-0.84)

0.76

PAPI

Values are n (%) or median (interquartile range). The Wilcoxon rank sum test was used for continuous variables,
and the chi-square test or Fisher exact test was used for categorical variables. Invasive hemodynamics were
reported in 281 patients in the Shock Team group and 262 patients in the No Shock Team group.
MAP ¼ mean arterial pressure; PAPI ¼ pulmonary artery pulsatility index; PCWP ¼ pulmonary capillary wedge
pressure.

for CS (n ¼ 1,242), CICU mortality was lower in those
admitted to CICUs at centers with versus without a
shock team (23% vs 29%; P ¼ 0.025) (Central
Illustration). Furthermore, the presence of a shock
team was independently associated with lower CICU
mortality in the IPW adjusted analysis (adjusted OR:

were treated in centers with shock teams. Patients

0.72; 95% CI: 0.55-0.94; P ¼ 0.016).

with CS at shock team centers were older and more

SUBGROUPS. The pattern of greater use of PACs,

commonly White (Table 2). Sex, prior history of heart

more advanced MCS, and lower mortality at shock

failure, illness severity by SOFA score, and rates of

team centers remained after stratifying groups by

both in-hospital and out-of-hospital cardiac arrest

acute myocardial infarction–related CS (AMI-CS)

were not different between groups (Table 2). Simi-

versus non–AMI-CS (Figure 2). Among admissions

larly, laboratory measures of end organ dysfunction

with AMI-CS, centers with a shock team used more

on CICU admission (lactate and creatinine) did not

PACs (adjusted OR: 2.38; 95% CI: 1.48-3.82; P < 0.001)

signiﬁcantly differ between cohorts.

and more advanced MCS (adjusted OR: 2.62; 95% CI:

The etiology of shock was well balanced between

1.44-4.75; P ¼ 0.002). In the non–AMI-CS cohort,

groups, including the proportion related to acute

shock team centers also used more PACs (adjusted

myocardial infarction (27% vs 28%) (Table 2). Left

OR: 1.62; 95% CI: 1.23-2.13; P ¼ 0.001); however, there

ventricular-predominant failure was most common,

was no difference in the use of advanced MCS

causes

(adjusted OR: 1.34; 95% CI: 0.81-2.23; P ¼ 0.26). The

(arrhythmia, valvular, tamponade, etc), and right

favorable patterns of association with lower CICU

ventricular-predominant failure. In the subset of CS

mortality among centers with shock teams persisted

admissions with available invasive hemodynamic

(P-interaction ¼ 0.11) among patients with AMI-CS

data (n ¼ 543), cardiac power output, and pulmonary

(adjusted OR: 0.79; 95% CI: 0.48-1.29; P ¼ 0.344)

artery pulsatility index were similar between groups

(Figure 2) and non–AMI-CS presentations (adjusted

(Table 3).

OR: 0.67; 95% CI: 0.49-0.93; P ¼ 0.017).

followed

SHOCK

by

biventricular

failure,

MANAGEMENT. Institutions

other

with

shock

teams had signiﬁcantly higher rates of PAC use (60%
vs 49%; adjusted odds ratio [OR]: 1.86; 95% CI: 1.472.35; P < 0.001) (Central Illustration), which were
typically placed in less than one-half of the time (0.3

Among the subgroup of patients who received
PACs, CICU mortality was lower at shock team centers
(21.2% vs 26.4%). In this subpopulation, we observed
that the shock team centers used less overall MCS
(43.6% vs 57.5%) and more commonly used advanced

vs 0.66 days; P ¼ 0.019) (Table 4). The median num-

forms of MCS (55.6% vs 45.9%).

ber of inotropic agents per patient was lower at shock

DISCUSSION

team centers. Centers with shock teams had lower
rates of overall MCS use (35% vs 43% of CS cases;

This study provides a novel multicenter analysis of

adjusted OR: 0.74; 95% CI: 0.59-0.95; P ¼ 0.016), used

advanced CICU practice patterns and outcomes in the

more advanced types of MCS overall (53% vs 43% of

treatment of CS in centers with versus without a

all MCS; adjusted OR: 1.73; 95% CI: 1.19-2.51;

shock team. We found that medical centers with

P ¼ 0.005), and more commonly chose advanced

shock teams used signiﬁcantly more PACs and

types of MCS as their initial device (42% vs 28% of CS

advanced types of MCS while using less MCS overall,

patients who received MCS; P ¼ 0.002) (Figure 1).

which was driven by less frequent use of intra-aortic

RESOURCE

the CS

balloon pumps. This preference toward advanced

cohort, patients treated at shock team centers had a

MCS was observed with regard to both initial and

USE

AND

OUTCOME. Within

Downloaded for library services (libraryservices@lvhn.org) at Lehigh Valley Health Network from ClinicalKey.com by Elsevier on
August 25, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

Papolos et al

JACC VOL. 78, NO. 13, 2021
SEPTEMBER 28, 2021:1309–1317

Cardiogenic Shock Outcomes With Shock Teams

C ENTR AL I LL U STRA T I O N Prototypical Shock Team Workﬂow and Associated Outcomes

Papolos, A.I. et al. J Am Coll Cardiol. 2021;78(13):1309–1317.

Prototypical shock team workﬂow and membership (top). Study population characteristics (bottom left). The proportion of patients admitted with cardiogenic shock
(CS) who received pulmonary artery catheters, mechanical circulatory support (MCS), advanced forms of MCS, and associated cardiac intensive care unit mortality
(bottom right). Advanced MCS included Impella (Abiomed), extracorporeal membrane oxygenation, TandemHeart (LivaNova), and temporary or durable surgical
ventricular assist devices. P values are adjusted for age, sex, Sequential Organ Failure Assessment score, cardiac arrest, hospital size, CS phenotype, and Society for
Cardiovascular Angiography & Interventions stage using inverse probability weighted modeling. *Advanced MCS rates were reported within subjects who received
MCS. AMI-CS ¼ acute myocardial infarction–related cardiogenic shock; CI ¼ cardiac index; CPO ¼ cardiac power output; ECMO ¼ extracorporeal membrane
oxygenation; PCWP ¼ pulmonary capillary wedge pressure; PAC ¼ pulmonary artery catheter; CICU ¼ cardiac intensive care unit.

overall MCS device selection. Patients with CS treated

model, the shock team could be activated by a single

at centers with shock teams had shorter CICU stays

call and bring together physicians from critical care

and lower rates of both mechanical ventilation and

cardiology, advanced heart failure and transplant

new renal replacement therapy. CICU mortality was

cardiology, interventional cardiology, and cardiac

lower in adjusted analyses in centers with shock

surgery to collaborate on patient care decisions and

teams.

streamline the delivery of care. When compared to

ACCUMULATING RATIONALE FOR SHOCK TEAMS.

historical data from their institution, implementation

Tehrani et al (6) described the development of a shock

of a shock team was associated with an increase in CS

team within a tertiary care medical center. In this

survivorship from 47% to 58% in the ﬁrst year and
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generally well balanced in terms of baseline char-

T A B L E 4 Clinical Course and Outcomes of Patients With Cardiogenic Shock

Clinical Course and Outcomes

Time from CICU admission to PAC, days
Median number of inotropes administered

acteristics, invasive hemodynamics, and markers of

Shock Team
(n ¼ 546)

No Shock Team
(n ¼ 696)

P Value

0.3 (0.08-1.00)

0.66 (0.15-1.58)

0.019

end organ damage. Centers with shock teams had
an estimated 28% lower adjusted relative odds of
CICU mortality.

1 (1-2)

2 (1-2)

0.008

223 (40.8)

363 (52.2)

<0.001

58 (10.6)

131 (18.8)

<0.001

relationship from this observational study, our ﬁnd-

4.0 (2.0-7.5)

5.1 (2.4-10.5)

<0.001

ings expand the available evidence supporting the

126 (23.1)

200 (28.7)

0.025

potential value of a shock team. We speculate that

Treated with any MCS

192 (35.2)

299 (43.0)

0.005

MCS before transfer

47 (24.5)

88 (29.6)

0.22

MCS during ﬁrst 24 hours

115 (59.9)

154 (51.9)

—

MCS after 24 hours

30 (15.6)

55 (18.5)

—

Mechanical ventilation
New renal replacement therapy
Duration of CICU stay, days
CICU mortality
MCS

Although it is not possible to conclude a causal

any effect associated with the presence of a shock
team is multifactorial in nature. First, the rapid
identiﬁcation and treatment of CS before the development of multiorgan dysfunction may contribute to
better survival, shorter CICU length of stay, and less

Values are median (interquartile range) or n (%). The Wilcoxon rank sum test used for continuous variables, and
the chi-square test or Fisher exact test was used for categorical variables. MCS rates were obtained within
subjects who received MCS. MCS timing was missing in 2 patients in the No Shock Team group.

need for renal replacement therapy and mechanical

CICU ¼ cardiac intensive care unit; MCS ¼ mechanical circulatory support; PAC ¼ pulmonary artery catheter.

use of PACs, as evident in our study, clarifying the

ventilation (11). Second, the early and more common
hemodynamic proﬁle and severity of left, right, or
biventricular failure driving the shock state may aid

77% in the second year (n ¼ 130/204). These ﬁndings

in therapeutic selection, MCS or otherwise (12-18).

were recapitulated in a similar single-center obser-

Although it is not possible for us to isolate all of

vational experience (n ¼ 123) that reported an in-

the elements of care that may differ in association

crease in CS survival from a historical baseline of 48%

with a shock team, when restricted to patients

to 61% after the implementation of a shock team (5).

who were treated with a PAC, the persistent pattern

In this study, we expand on the current evidence

of lower mortality among shock team centers in-

with an observational analysis with >1,200 admis-

dicates that this difference is not related solely to

sions

of

increased use of PACs at shock team centers. It is

advanced CICUs in North America. In this analysis

possible that both differences in experience with the

inclusive of broad CS etiologies, the cohorts from

interpretation of invasive hemodynamic data and

centers with versus without a shock team were

other aspects of care enhanced by the integration of

for

CS

from

a

multicenter

network

F I G U R E 1 Initial MCS Device by Centers With Versus Without Shock Teams

P = 0.002
72%
58%

P = 0.001
28%
16%

IABP
(n = 317)

Impella
(n = 98)

P = 0.028
5%
1%
Tandem
(n = 28)

Shock Team

P = NS
9% 11%
ECMO
(n = 34)

P = NS
1%
0%
Temporary
Surgical VAD
(n = 3)

No Shock Team

The proportion of initial mechanical circulatory support (MCS) device use at centers with versus without shock teams. Rates are reported
within subjects who received MCS. ECMO ¼ extracorporeal membrane oxygenation; IABP ¼ intra-aortic balloon pump; NS ¼ nonsigniﬁcant;
Tandem ¼ TandemHeart; VAD ¼ ventricular assist device.
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F I G U R E 2 Outcomes in Acute and Nonacute Myocardial Infarction–Related CS

Odds Ratio
(95% CI)

P Value

AMI-CS

2.38 (1.48-3.82)

<0.001

Non-AMI-CS

1.62 (1.23-2.13)

0.001

Overall

1.86 (1.47-2.35)

<0.001

AMI-CS

2.62 (1.44-4.75)

0.002

Non-AMI-CS

1.34 (0.81-2.23)

0.26

Overall

1.73 (1.19-2.51)

0.005

AMI-CS

0.79 (0.48-1.29)

0.34

Non-AMI-CS

0.67 (0.49-0.93)

0.017

Overall

0.72 (0.55-0.94)

0.016

Pulmonary Artery Catheter Use

Advanced MCS Use

CICU Mortality

0.15

0.3 0.5 0.7 1 1.5 2
Presence of Shock Team

3

Practice patterns and outcomes in acute and nonacute myocardial infarction–related cardiogenic shock in centers with versus without shock
teams. The P values presented are adjusted for age, sex, sequential organ failure assessment score, in-hospital and out-of-hospital cardiac
arrest preceding shock presentation, hospital size, CS phenotype (left ventricular, right ventricular, or biventricular failure or other) and
Society for Cardiovascular Angiography and Interventions CS stage using inverse probability weighted modeling. Advanced MCS included
Impella (Abiomed), TandemHeart (LivaNova), extracorporeal membrane oxygenation, and temporary or durable surgical ventricular assist
devices. AMI-CS ¼ acute myocardial infarction–related cardiogenic shock; CICU ¼ cardiac intensive care unit; CS ¼ cardiogenic shock;
MCS ¼ mechanical circulatory support; non–AMI-CS ¼ nonacute myocardial infarction cardiogenic shock.

a shock team might contribute to the observed

selection in parallel with its deployment and man-

difference in mortality. Third, a structured, team-

agement strategy (19).

based evaluation that incorporates patient-centric

STUDY STRENGTHS AND LIMITATIONS. The study

characteristics and institutional-speciﬁc capabilities

population was derived from a well-characterized multi-

may facilitate timely and optimal MCS device

center

clinical

registry

comprising

medical

CICU
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admissions, which offers higher data ﬁdelity than

CONCLUSIONS

administrative databases. In capturing contemporary
practice patterns across a broad group of centers and being

Centers with shock teams use more invasive hemo-

inclusive of all consecutive CICU patients with CS during

dynamic monitoring and advanced MCS devices while

the study period, the sample may offer a more realistic

using less MCS overall. Centers with shock teams

estimate of a possible effect size than prior studies.

appear to have higher CS-related CICU survival and

This analysis is subject to the limitations of an

reduced

CICU

resource

use.

Our

data

support

observational study. While we have used a rigorous

considering the implementation of shock teams at

approach with inverse probability weighting, we

tertiary cardiovascular centers.

cannot eliminate the possibility of residual confounding. Also, patients with CS who were not

FUNDING SUPPORT AND AUTHOR DISCLOSURES

managed in the CICU were not captured in the regis-

Dr Drakos has served as a consultant to Abbott. Dr Sinha has served as

try. Further to this point, in many centers ECMO is

a consultant to the Abiomed Critical Care Advisory Board. All other

exclusively managed in the cardiac surgery intensive

authors have reported that they have no relationships relevant to the

care unit (ICU). As data collection was restricted to

contents of this paper to disclose.

the CICU, total ICU resource utilization was not
captured in patients transferred to other ICUs (eg, in
cases of transfer to a cardiac surgery ICU for ECMO).
We expect this limitation to have minimal impact
given that there was no signiﬁcant difference in
ECMO utilization between groups.
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Another consideration is that the shock teams in
the current analysis were individual institutionallydriven initiatives that formed to meet the needs and

PERSPECTIVES

limitations of the parent institutions, and as such
there is no standardization from one team to another.

COMPETENCY IN SYSTEMS-BASED PRACTICE:

Our dataset also does not capture the time of CS

Multidisciplinary, integrated shock teams may

onset, and therefore the time from shock onset to

expedite evaluation and therapy of patients with

circulatory support could not be directly examined.

cardiogenic shock, improve survival, and reduce

Data on inotropic strategies, sedation practices, and

resource utilization.

ventilator management were similarly limited. In
addition, apart from hospital size, differences between centers were not incorporated into the primary
analysis. Other study site characteristics, such as
variations in catchment area, were also not captured
in this registry and therefore could not be evaluated

TRANSLATIONAL OUTLOOK: Further efforts are
needed to identify and overcome impediments to
implementation of cardiogenic shock teams in diverse
communities and establish criteria for prioritizing
them over other hospital initiatives.

as potential confounders.
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